BiotechTube

Moroctocog alfa(AF-CC)

ApprovedTerminated
0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Hemophilia A

Conditions

Hemophilia A

Trial Timeline

Feb 1, 2009 → Aug 1, 2011

NCT ID
NCT00765726

About Moroctocog alfa(AF-CC)

Moroctocog alfa(AF-CC) is a approved stage product being developed by Pfizer for Hemophilia A. The current trial status is terminated. This product is registered under clinical trial identifier NCT00765726. Target conditions include Hemophilia A.

What happened to similar drugs?

20 of 20 similar drugs in Hemophilia A were approved

Approved (20) Terminated (2) Active (0)
✅EmicizumabRocheApproved
✅BenefixPfizerApproved
✅Nonacog alfaPfizerApproved
✅moroctocog alfa (AF-CC) (ReFacto AF)PfizerApproved
✅Recombinant Factor IX CoagulationPfizerApproved
✅Factor IX recoveryPfizerApproved
✅Moroctocog alfa ( AF-CC)PfizerApproved

Hype Score Breakdown

Clinical
20
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00765726ApprovedTerminated

Competing Products

20 competing products in Hemophilia A

See all competitors
ProductCompanyStageHype Score
EmicizumabChugai PharmaceuticalPhase 3
40
EmicizumabChugai PharmaceuticalPhase 3
40
Emicizumab + rFVIIa + aPCCChugai PharmaceuticalPhase 3
40
Human Coagulation Factor VIIIChugai PharmaceuticalPhase 3
47
EmicizumabChugai PharmaceuticalPhase 3
47
Emicizumab + Factor VIII (FVIII)Chugai PharmaceuticalPhase 3
40
EmicizumabRochePhase 3
40
HEMLIBRAJohnson & JohnsonPre-clinical
26
EmicizumabRochePhase 3
40
EmicizumabRocheApproved
47
EmicizumabRochePhase 3
44
SPK-8011QQRochePhase 1/2
39
NXT007RochePhase 1/2
39
Emicizumab InjectionRochePhase 2
35
Bypassing Agents + FVIII ReplacementRochePre-clinical
26
PF-06741086 + PF-06741086 + PF-06741086 + PF-06741086PfizerPhase 2
35
Nonacog Alfa (Genetical Recombination)PfizerPre-clinical
26
Refacto AFPfizerPre-clinical
18
PF-06838435/ fidanacogene elaparvovecPfizerPhase 3
44
ReFacto AFPfizerPhase 3
40